BRAF V600 mutation-positive advanced non-small cell lung cancer (NSCLC) can be treated with targeted therapies that specifically inhibit the BRAF V600 mutation. These include:
Dabrafenib is a selective inhibitor of the BRAF kinase that has been shown to be effective in treating NSCLC patients with the BRAF V600E mutation. It works by blocking the activity of the mutated BRAF protein, thereby inhibiting tumor cell growth and survival.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203088s007lbl.pdf|
Trametinib is a selective inhibitor of MEK1 and MEK2, which are downstream components of the RAS-RAF-MEK-ERK signaling pathway. By inhibiting MEK, trametinib can block the growth and survival signals in BRAF V600E mutated NSCLC cells. Trametinib is often used in combination with dabrafenib to enhance the treatment efficacy.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203089s007lbl.pdf|
The combination of dabrafenib and trametinib has been approved by the FDA for the treatment of metastatic NSCLC patients with the BRAF V600E mutation who have not received prior systemic therapy for their metastatic disease.